Bakkt Reports Second Quarter 2026 Results
- GAAP net income of
- Six commercial offerings live across Bakkt Markets; Total Transacting Volume (“TTV”) of
- Bakkt Agent Embedded Finance available for partner integration today; initial co-branded card programs and Neobank-as-a-Service offerings targeted for Q4 2026
- Cash, cash equivalents and restricted cash of
- Received Indian regulatory approvals and completed the allotment of 47.5 million Transchem warrants in June; position carried at a fair value of
Management Commentary:
"
“In Bakkt Markets, we processed approximately
Bakkt Agent progressed from architecture to commercial availability for partner integration. Our
Bakkt Global also reached an important milestone. Following the receipt of the required regulatory approvals in
Recent Operational Updates:
- Transchem Investment Approval (
India ): Following receipt of required Indian regulatory approvals, Transchem Limited (BSE: 500422) allotted 47,500,000 warrants toBakkt inJune 2026 .Bakkt paid approximately$9.4 million , representing 25% of the aggregate subscription amount, and may exercise the warrants in one or more tranches within 18 months of issuance; the remaining aggregate subscription amount upon full exercise was approximately$28.2 million as ofJune 30, 2026 . The position is carried at fair value, with changes recognized in earnings each period. - DTR Integration: Integration of the payment, stablecoin, onboarding and compliance technology acquired on
April 30, 2026 advanced during the quarter: onboarding and identity processes were consolidated across product modules, and wire and ACH funding capabilities went live, connecting traditional bank rails to stablecoin settlement within a single API. BeginningMay 1, 2026 , payments activity processed through the acquired infrastructure is included in Total Transacting Volume. Commercial Organization : The Company strengthened its go-to-market capability during the quarter under Chief Commercial OfficerDaniel Ishag , who now leads a unified Commercial department with an expanded and strengthened sales team. The team is actively bringing the platform’s available products to market, including digital asset trading and OTC execution, stablecoin on- and off-ramps, cross-border payments through the Zaira API, the Bakkt Widget, and Bakkt Agent Embedded Finance modules.- Bakkt Agent and Neobank-as-a-Service: Bakkt Agent Embedded Finance, including accounts, payments and international transfers as modules on
Bakkt's regulated stack, is available for partner integration now. A conversational interface on those rails, designed to let an end customer ask, understand and act in plain language, is targeted for Q4 2026, as are initial co-branded card programs; certain products remain subject to partner, bank, network and regulatory requirements. The Company's Neobank-as-a-Service offering, which demonstrates what clients can launch under their own brands, spans everyday money end to end: getting paid, spending, saving, sending and account control. The initial version is targeted for Q4 2026 and remains subject to product readiness, client launch timing, bank and network requirements, and applicable approvals.
Q2 2026 Financial Results and Discussion:
| $ in millions | Q2’26 | Q2’25 | Increase/ (decrease) |
|||||
| Total revenue | $ | 170.1 | $ | 568.1 | (70.0 | )% | ||
| Operating expenses | ||||||||
| Crypto costs and execution, clearing and brokerage fees (“ECB”) | 169.3 | 565.2 | (70.1 | )% | ||||
| Operating expenses, excluding crypto costs and ECB | 20.5 | 19.0 | 7.9 | % | ||||
| Total operating expenses | 189.8 | 584.2 | (67.5 | )% | ||||
| Net income (loss) attributable to |
80.8 | (14.7 | ) | NM | ||||
| Adjusted EBITDA loss (Non-GAAP)1 | $ | (11.8 | ) | $ | (9.8 | ) | NM | |
1. Adjusted EBITDA is a non-GAAP financial measure. Adjusted EBITDA also excludes transaction-related advisory fees, as shown in the reconciliation below. See “Reconciliation of Non-GAAP Financial Measures.”
- Total revenue was
$170.1 million , compared with$568.1 million in Q2 2025, reflecting previously disclosed client transitions and industry-wide softness in digital asset trading volumes. The substantial majority of that figure is offset by corresponding crypto costs and execution, clearing and brokerage fees, which totaled$169.3 million in the quarter. - Total operating expenses were
$189.8 million , compared with$584.2 million in Q2 2025. Excluding crypto costs and execution-related fees, operating expenses were approximately$20.5 million , including a$1.2 million non-cash impairment of long-lived assets and$1.1 million of depreciation and amortization primarily from acquired DTR intangibles. The year-over-year change primarily reflects two months of acquired DTR operating costs and professional-services expenses supporting the DTR integration andIndia strategy. - Net income attributable to
Bakkt was$80.8 million , or$1.96 per basic and$1.94 per diluted share, compared with a net loss attributable toBakkt of$14.7 million in Q2 2025. The current quarter includes a$98.5 million non-cash gain from the change in fair value of the Transchem warrants, reported as a separate line item, and a$1.4 million non-cash gain from the change in fair value of a legacy warrant liability. - Adjusted EBITDA loss was
$11.8 million , compared with$9.8 million in Q2 2025 on a continuing-operations basis, an increase in loss of$2.0 million . The change was primarily due to a$2.0 million decrease in crypto services revenue net of crypto costs and execution, clearing and brokerage fees, a$0.7 million increase in salaries and contract labor, and a$0.3 million loss from an equity method investment that did not occur in the prior-year period, partially offset by a$0.9 million reduction in selling, general and administrative expenses. Adjusted EBITDA excludes$3.6 million of transaction-related advisory fees, which are not expected to recur at this level and are shown separately in the reconciliation, as well as the non-cash fair-value changes in the Transchem warrants and a legacy warrant liability. - Cash, cash equivalents and restricted cash were
$50.7 million as ofJune 30, 2026 , compared with$27.5 million atDecember 31, 2025 , after funding the approximately$9.4 million initial Transchem subscription payment. Sources of liquidity in H1 2026 included approximately$48.1 million of gross proceeds from the February registered direct offering and$21.5 million of proceeds from sales under the Company’s at-the-market (“ATM”) offering. The Company ended the quarter with no long-term debt, providing flexibility to continue investing in commercial activation with discipline.
Key Performance Indicators:
- Total Transacting Volume (TTV) was
$168.8 million for Q2 2026 and$410.0 million for the six months endedJune 30, 2026 . Because crypto services revenue is presented on a gross basis, the notional value of digital asset transactions in TTV is generally also recognized as revenue, with substantially offsetting costs; for payments activity, the associated fees and spreads, rather than the notional value, are recognized as revenue. TTV is an operating metric and does not represent profitability, assets held by the Company, or cash flow. The Company continues to expect TTV of approximately$2.5 billion for full-year 2026. This expectation is a forward-looking statement and is subject to the risks and uncertainties described under "Note on Forward-Looking Statements." It assumes that client integrations and activations currently underway progress through compliance and launch stages on the timelines management currently anticipates, with activity ramping in the second half of 2026, and that transaction levels on the platform remain consistent with recent experience. Actual results will depend on client implementation, partner and regulatory requirements, and market conditions, and may differ materially. - Strategic Asset Value (SAV) was approximately
$118.6 million as ofJune 30, 2026 , equal to the aggregate value of the Company’s Bakkt Global strategic positions as reported in its consolidated balance sheet: the sum of the carrying value of the Company’s equity method investment in Bitcoin Japan Corporation at$10.6 million and the fair value of its Transchem warrant position at$107.9 million . SAV does not represent a market or liquidation value of the underlying positions, and actual realizable value may differ materially. - Monthly Active Users (MAUs). A Monthly Active User is a unique end user completing at least one qualifying activity in an applicable Bakkt Agent-powered product during the calendar month. Management currently expects MAUs to reach approximately 25,000 in
December 2026 as partner products activate and begin generating qualifying end-user activity. This expectation is a forward-looking statement and is subject to the risks and uncertainties described under “Note on Forward-Looking Statements.” It assumes that initial Bakkt Agent-powered partner products, including co-branded card programs and the Company's Neobank-as-a-Service offering, launch commercially in the fourth quarter of 2026 as currently targeted, and that partners begin onboarding end users following launch. Actual results will depend on timing, client implementation, partner and regulatory requirements, and end-user adoption, and may differ materially.
Webcast and Conference Call Information
Conference Call Details:
- Day:
Monday, August 10, 2026 - Time:
5:30 PM ET - Participant Call Links:
About
For more information, visit: https://www.bakkt.com/ | X | LinkedIn | Instagram
Investor Relations
bakkt@orangegroupadvisors.com
Media
Luna PR
bakkt@lunapr.io
Note on Forward-Looking Statements
This release and the accompanying remarks contain “forward-looking statements” within the meaning of Section 27A of the
You should not place undue reliance on these forward-looking statements. Should one or more known or unknown risks and uncertainties materialize, or should any of our assumptions prove incorrect, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to: the Company’s ability to grow and manage growth profitably; whether the Company will be able to successfully integrate its operations with those of DTR, including its infrastructure, and achieve the expected benefits therefrom; the operation, reliability, market acceptance and regulatory environment for digital assets, stablecoin-based payment systems and digital settlement infrastructure; changes in the Company’s business strategy; the Company's adoption of its updated Investment Policy (“Investment Policy”) and related treasury strategy, including the Company’s ability to successfully consummate acquisitions, integrate or manage investments in potential acquisition targets and investees; the price of digital assets, including Bitcoin; risks associated with operating in the digital asset industry, including price volatility, limited liquidity and trading volumes, relative anonymity, potential widespread susceptibility to market abuse and manipulation, compliance and internal control failures at exchanges and other risks inherent in its entirely electronic, virtual form and decentralized network; the fluctuation of the Company’s operating results, including because the Company may be required to account for its digital assets at fair value; the Company’s ability to time the price of its purchase of digital assets pursuant to its strategy; the impact of the market value of digital assets on the Company’s ability to satisfy its financial obligations, including any debt financings; unrealized fair value gains on its digital asset holdings subjecting the Company to the corporate alternative minimum tax; legal, commercial, regulatory and technical uncertainty regarding digital assets and enhanced regulatory oversight of companies holding digital assets including the possibility that regulators reclassify any digital assets held by the Company, including Bitcoin, as a security causing the Company to be in violation of securities laws and be classified as an “investment company” under the Investment Company Act of 1940; enhanced regulatory oversight as a result of the Company’s Investment Policy and related treasury strategy; the possibility of experiencing greater fraud, security failures or operational problems on digital asset trading venues compared to trading venues for more established asset classes, and any malfunction, breakdown or abandonment of the underlying blockchain protocols, or other technological difficulties, may prevent access to or use of such digital assets; the concentration of the Company’s expected digital asset holdings relative to non-digital assets; the inability to use the Company’s digital asset holdings as a source of liquidity to the same extent as cash and cash equivalents, due to, for example, risks associated with digital assets and other risks inherent to its entirely electronic, virtual form and decentralized network; the Company or a third-party service provider experiencing a security breach or cyber-attack where unauthorized parties obtain access to its digital assets; the loss of access to or theft or data loss of the Company’s or its customers’ digital assets, which could be unrecoverable due to the immutable nature of blockchain transactions; if the Company elects to hold its or its customers’ digital assets through a third-party custodian, the loss of direct control over those digital assets and dependence on the custodian’s security practices and operational integrity which may lead to the loss of those digital assets as a result of the insolvency of the custodian, theft by employees or insiders of the custodian or if the custodian’s security measures are compromised, including as a result of a cyber-attack; the Company not being subject to the legal and regulatory protections applicable to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers; the non-performance, breach of contract or other violations by counterparties assisting the Company in effecting its Investment Policy and related treasury strategy; the Company’s future capital requirements and sources and uses of cash, including funds to satisfy its liquidity needs; the Company’s ability to raise capital and investments in us, including by our Chief Executive Officer; changes in the market in which the Company competes, including with respect to its competitive landscape, technology evolution or changes in applicable laws or regulations; changes in the markets that the Company targets; volatility and disruptions in the digital asset, digital payments and stablecoin markets that subject the Company to additional risks, including the risk that banks may not provide banking services to the Company and market sentiments regarding digital assets, digital payments and stablecoins; the possibility that the Company may be adversely affected by other macroeconomic, geopolitical, business, and/or competitive factors; the Company’s ability to launch new services and products, including with its expected commercial partners, or to profitably expand into new markets and services; the Company’s ability to execute its growth strategies, including identifying and executing acquisitions and divestitures and the Company’s initiatives to add new clients; the Company’s ability to reach definitive agreements with its expected commercial counterparties; the Company’s failure to comply with extensive government regulations, oversight, licensure and appraisals; uncertain and evolving regulatory regime governing blockchain technologies, stablecoins, digital payments and digital assets; the Company’s ability to establish and maintain effective internal controls and procedures; the exposure to any liability, protracted and costly litigation or reputational damage relating to the Company’s data security; the impact of any goodwill or other intangible assets impairments on the Company’s operating results; the Company’s ability to maintain the listing of its securities on the
Consolidated Balance Sheets |
|||||||
| $ in thousands | As of (unaudited) |
As of |
|||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 49,980 | $ | 26,962 | |||
| Restricted cash | 718 | 575 | |||||
| Customer funds | 20,582 | 14,662 | |||||
| Investments | 311 | 235 | |||||
| Accounts receivable, net | 11,276 | 12,070 | |||||
| Prepaid insurance | 924 | 2,749 | |||||
| Other current assets | 13,609 | 14,947 | |||||
| Total current assets | 97,400 | 72,200 | |||||
| Property, equipment and software, net | 2,085 | 1,660 | |||||
| 156,690 | 64,658 | ||||||
| Intangible assets | 22,862 | 5,550 | |||||
| Equity method investment | 10,645 | 11,149 | |||||
| Derivative Asset | — | 3,352 | |||||
| Transchem Warrants | 107,906 | — | |||||
| Other assets | 6,012 | 4,219 | |||||
| Total assets | $ | 403,600 | $ | 162,788 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | $ | 9,847 | $ | 14,876 | |||
| Customer funds payable | 20,582 | 14,662 | |||||
| Deferred revenue, current | — | 789 | |||||
| Other current liabilities | 591 | 2,703 | |||||
| Total current liabilities | 31,020 | 33,030 | |||||
| Warrant liability | 10,616 | 16,732 | |||||
| Other noncurrent liabilities | 7,574 | 244 | |||||
| Total liabilities | 49,210 | 50,006 | |||||
| Stockholders' equity | |||||||
| Class A Common Stock ( |
4 | 3 | |||||
| Additional paid-in capital | 1,189,365 | 1,017,004 | |||||
| Accumulated other comprehensive loss | 1,001 | 947 | |||||
| Accumulated deficit | (835,980 | ) | (905,172 | ) | |||
| Total equity | 354,390 | 112,782 | |||||
| Total liabilities and stockholders' equity | $ | 403,600 | $ | 162,788 | |||
| Consolidated Statements of Operations | ||||||
| $ in thousands except per share data | Q2’26 (Unaudited) |
Q2’25 (Unaudited) |
||||
| Revenues: | ||||||
| Crypto services | $ | 170,149 | $ | 568,103 | ||
| Total Revenues | 170,149 | 568,103 | ||||
| Operating expenses: | ||||||
| Crypto costs | 167,938 | 561,074 | ||||
| Execution, clearing and brokerage fees | 1,318 | 4,139 | ||||
| Compensation and benefits | 6,958 | 10,169 | ||||
| Professional services | 7,194 | 4,028 | ||||
| Technology and communication | 1,700 | 1,345 | ||||
| Selling, general and administrative | 2,330 | 3,271 | ||||
| Depreciation and amortization | 1,052 | 154 | ||||
| Impairment of long-lived assets | 1,246 | — | ||||
| Other operating expenses | 26 | 44 | ||||
| Total operating expenses | 189,762 | 584,224 | ||||
| Operating loss from continuing operations | (19,613 | ) | (16,121 | ) | ||
| Interest income (expense), net | 547 | (53 | ) | |||
| Change in fair value of warrant liability | 1,416 | (8,604 | ) | |||
| Change in fair value of Transchem warrant | 98,496 | — | ||||
| Other income (expense), net | 284 | (2,038 | ) | |||
| Income (loss) from continuing operations before income taxes and equity in net earnings of affiliates | 81,130 | (26,816 | ) | |||
| Income tax expense | (5 | ) | (76 | ) | ||
| Net income (loss) from continuing operations before equity in net earnings of affiliates | 81,125 | (26,892 | ) | |||
| Loss from equity method investment | (283 | ) | — | |||
| Net income (loss) from continuing operations | 80,842 | (26,892 | ) | |||
| Net loss from discontinued operations, net of tax | — | (3,260 | ) | |||
| Net income (loss) | 80,842 | (30,152 | ) | |||
| Less: Net income attributable to noncontrolling interest | — | (15,418 | ) | |||
| Net income (loss) attributable to |
$ | 80,842 | $ | (14,734 | ) | |
| Net income (loss) per share attributable to Class A common stockholders | ||||||
| Basic | $ | 1.96 | $ | (2.16 | ) | |
| Diluted | $ | 1.94 | $ | (2.16 | ) | |
| Consolidated Statements of Cash Flows | |||||||
| $ in thousands | 6 Months Ended (Unaudited) |
6 Months Ended (Unaudited) |
|||||
| Cash flows from operating activities: | |||||||
| Net (loss) income | 69,191 | $ | (13,915 | ) | |||
| Adjustments to reconcile loss to net cash (used in) provided by operating activities: | |||||||
| Depreciation and amortization | 1,118 | 374 | |||||
| Non-cash lease expense | — | 566 | |||||
| Share-based compensation expense | 4,697 | 9,681 | |||||
| Impairment of long-lived assets | 1,246 | — | |||||
| Loss on sale of |
— | 2,301 | |||||
| Gain on lease assignment | — | (1,755 | ) | ||||
| Gain from change in fair value of warrant liability | (6,116 | ) | (23,644 | ) | |||
| Loss on equity method investment | 504 | — | |||||
| Change in fair value of Transchem warrant and derivative asset | (97,820 | ) | — | ||||
| Professional fees paid in stock | 1,125 | — | |||||
| Other | 58 | 87 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (349 | ) | 1,672 | ||||
| Prepaid insurance | 1,824 | 1,904 | |||||
| Deposits with clearing house | — | — | |||||
| Accounts payable and accrued liabilities | (5,029 | ) | 3,592 | ||||
| Unsettled crypto trades | (1,304 | ) | — | ||||
| Due to related party | — | (2,360 | ) | ||||
| Deferred revenue | (745 | ) | (535 | ) | |||
| Operating lease liabilities | (573 | ) | (2,698 | ) | |||
| Customer funds payable | 5,920 | (67,230 | ) | ||||
| Assets and liabilities of businesses held for sale | — | (3,476 | ) | ||||
| Other assets and liabilities | (657 | ) | (493 | ) | |||
| Net cash used in operating activities | (26,910 | ) | (95,929 | ) | |||
| Cash flows from investing activities: | |||||||
| Capitalized internal-use software development costs and other capital expenditures | (1,987 | ) | (149 | ) | |||
| Proceeds from Sale of |
— | 4,518 | |||||
| Cash received from settlement of derivative arrangement | 2,677 | — | |||||
| Purchase of investments | (14 | ) | — | ||||
| Consideration for the acquisition of DTR | (3,200 | ) | — | ||||
| Consideration for the acquisition of Gyzer | (253 | ) | — | ||||
| Investment in Swan | (250 | ) | — | ||||
| Investment in Transchem warrant | (9,410 | ) | — | ||||
| Net cash (used in) provided by investing activities | (12,437 | ) | 4,369 | ||||
| Cash flows from financing activities: | |||||||
| Proceeds from the exercise of warrants | — | 1 | |||||
| Withholding tax payments on net share settlements on equity awards | (329 | ) | (1,712 | ) | |||
| Proceeds from Equity offerings | 69,602 | — | |||||
| Cash paid for Equity offerings | (2,541 | ) | — | ||||
| Exercise of stock options | 500 | — | |||||
| Proceeds from borrowings on revolving credit facility | — | 5,000 | |||||
| Repayments on revolving credit facility | — | (5,000 | ) | ||||
| Cash paid for financing costs | — | (775 | ) | ||||
| Proceeds from issuance of convertible debentures, net of issuance costs | — | $ | 23,750 | ||||
| Net cash provided by financing activities | 67,232 | 21,264 | |||||
| Effect of exchange rate changes | 54 | 915 | |||||
| Net increase (decrease) in cash, cash equivalents, restricted cash, customer funds and deposits | 27,939 | (69,381 | ) | ||||
| Cash, cash equivalents, restricted cash, customer funds and deposits at the beginning of the period | 44,902 | 153,746 | |||||
| Cash, cash equivalents, restricted cash, customer funds and deposits at the end of the period | $ | 72,841 | $ | 84,365 | |||
| Reconciliation of Non-GAAP Financial Measures | |||||||
This release includes discussions of non-GAAP financial measures such as EBITDA and Adjusted EBITDA, which are financial measures that are not calculated in accordance with GAAP. These non-GAAP measures have no standardized meaning and are not defined under GAAP and, therefore, may not be comparable to similar measures presented by other companies. The presentation of these Non-GAAP measures is not intended to be considered in isolation from, as a substitute for, or as superior to the financial information presented in accordance with GAAP. The Company uses non-GAAP financial measures to assist in evaluating its performance for purposes of business decision-making. The Company believes that presenting non-GAAP financial measures is useful to investors because it (a) provides investors with meaningful supplemental information regarding financial performance by excluding certain items that we believe do not directly reflect our core operations, (b) permits investors to view performance using the same tools that we use to budget, forecast, make operating and strategic decisions, and evaluate historical performance, and (c) otherwise provides supplemental information that may be useful to investors in evaluating our results. These measures are provided on a supplemental basis for transparency and comparability, and do not modify reported GAAP financial results.
EBITDA and Adjusted EBITDA
Non-GAAP financial measures like EBITDA and Adjusted EBITDA have no standardized meanings and are not defined by accounting principles generally accepted in
| Non-GAAP Adjusted EBITDA Reconciliation | ||||||
| $ in thousands | Q2’26 |
Q2’25 |
||||
| Net income (loss) from continuing operations | $ | 80,842 | $ | (26,892 | ) | |
| Depreciation and amortization | 1,052 | 154 | ||||
| Interest (income) expense, net | (547 | ) | 53 | |||
| Income tax expense | 5 | 76 | ||||
| EBITDA | $ | 81,352 | $ | (26,609 | ) | |
| Share-based and unit-based compensation expense | 1,892 | 5,791 | ||||
| Change in fair value of warrant liability | (1,416 | ) | 8,604 | |||
| Change in fair value of Transchem warrant | (98,496 | ) | — | |||
| Impairment of long-lived assets | 1,246 | — | ||||
| Transaction-related advisory fees | 3,625 | — | ||||
| Loss on sale of |
— | 2,307 | ||||
| Debt issuance cost | — | 87 | ||||
| Adjusted EBITDA loss | $ | (11,797 | ) | $ | (9,820 | ) |
Source: Bakkt, Inc.